Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EXFORGE HCT vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EXFORGE HCT is a combination of amlodipine (a dihydropyridine calcium channel blocker), valsartan (an angiotensin II receptor blocker), and hydrochlorothiazide (a thiazide diuretic). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation. Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Hydrochlorothiazide increases excretion of sodium and water by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension: treatment of hypertension to lower blood pressure (FDA-approved)
Hypertension
One tablet orally once daily. Initial dose based on previous antihypertensive therapy; maximum dose is one tablet of 10 mg amlodipine/320 mg valsartan/25 mg hydrochlorothiazide per day.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Valsartan: 6 hours (terminal). Amlodipine: 30-50 hours (terminal), permits once-daily dosing. Hydrochlorothiazide: 6-15 hours (terminal).
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Amlodipine is extensively metabolized in the liver via CYP3A4; valsartan is minimally metabolized (about 20%) via CYP2C9; hydrochlorothiazide is not metabolized and is excreted unchanged.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Valsartan: 13% excreted unchanged in urine, 83% in feces via biliary secretion. Amlodipine: 10% excreted unchanged in urine, 60% as metabolites in urine, 20-25% in feces. Hydrochlorothiazide: ≥95% excreted unchanged in urine.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Valsartan: 94-97% (primarily albumin). Amlodipine: ~93% (albumin). Hydrochlorothiazide: 40-68% (albumin).
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Valsartan: 17 L (0.24 L/kg); indicates limited extravascular distribution. Amlodipine: 21 L/kg; extensive tissue distribution. Hydrochlorothiazide: 3-15 L (0.05-0.2 L/kg); distributes into extracellular fluid.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: Valsartan 25% (wide range 10-35%), amlodipine 64-90%, hydrochlorothiazide 65-75%.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
Contraindicated in anuria. For GFR 30-60 m L/min: no dose adjustment needed, but monitor serum potassium and creatinine. For GFR <30 m L/min: not recommended due to limited data.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh Class A: no adjustment; Class B: maximum dose 5 mg amlodipine/160 mg valsartan/12.5 mg hydrochlorothiazide; Class C: not recommended.
Child-Pugh Class B or C: contraindicated; use not recommended.
Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosing.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Initiate at the lowest available dose (5 mg amlodipine/160 mg valsartan/12.5 mg hydrochlorothiazide) and titrate slowly; monitor renal function, electrolytes, and blood pressure due to increased risk of hypotension and electrolyte imbalance.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
WARNING: FETAL TOXICITY. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.
None
Fetal toxicity: avoid use in pregnancy; discontinue if pregnancy occurs.,Hypotension: symptomatic hypotension may occur, especially in volume-depleted patients.,Electrolyte and metabolic effects: hydrochlorothiazide may cause hypokalemia, hyponatremia, hypercalcemia, hypomagnesemia, and hyperglycemia.,Renal function deterioration: monitor renal function; may cause acute renal failure.,Hepatic impairment: use caution in patients with severe hepatic impairment.,Angioedema: reported with valsartan; monitor for swelling of face, lips, throat.,Avoid concomitant use with aliskiren in patients with diabetes or renal impairment.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to any component.,Anuria (due to hydrochlorothiazide).,Concomitant use with aliskiren in patients with diabetes mellitus.,Severe renal impairment (e GFR <30 m L/min/1.73 m²).,Pregnancy (second and third trimesters).,Hereditary fructose intolerance (due to sorbitol excipient in some formulations).
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid high-potassium foods (bananas, oranges, spinach, potatoes) and salt substitutes with potassium unless instructed otherwise. Grapefruit juice may increase amlodipine levels; limit consumption. Alcohol may enhance hypotensive effects. Maintain adequate fluid intake to prevent dehydration.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: Drugs acting on renin-angiotensin system (ARB/ACEi component: valsartan) associated with increased risk of fetal renal dysfunction, oligohydramnios, skull ossification defects, and fetal death if exposed during first trimester. However, major teratogenic risk is primarily second and third trimester. Hydrochlorothiazide (HCTZ) may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Second and third trimester: Valsartan exposure is associated with oligohydramnios, fetal renal failure, skull hypoplasia, anuria, and death. HCTZ can cause fetal electrolyte imbalances, jaundice, and thrombocytopenia. Avoid use in pregnancy, especially second and third trimesters.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Valsartan: Not known if excreted in human milk; due to potential for adverse effects on infant kidney function, caution advised. Hydrochlorothiazide: Excreted in breast milk in small amounts; M/P ratio approximately 0.6. May suppress lactation. Use only if clearly needed, monitoring infant for electrolyte disturbances and dehydration.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
Not recommended for use in pregnancy. If unavoidable, use lowest effective dose; however, pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may require dose adjustments, but safety data insufficient. Generally, avoid use.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Exforge HCT is a triple combination of amlodipine, valsartan, and hydrochlorothiazide. It is indicated for hypertension not adequately controlled on dual therapy. Monitor serum potassium, especially in patients with renal impairment or on NSAIDs. Avoid use in pregnancy due to direct renin-angiotensin system effects. Titrate doses based on blood pressure response. Common side effects include peripheral edema (amlodipine), dizziness, and electrolyte disturbances (HCTZ).
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take exactly as prescribed, usually once daily with or without food.,Do not stop taking this medication without consulting your doctor.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) or low blood pressure (dizziness, fainting).,Avoid potassium supplements or salt substitutes containing potassium unless advised by your doctor.,Limit alcohol intake as it may increase blood pressure or cause dizziness.,If pregnant or planning pregnancy, inform your doctor immediately as this drug can harm an unborn baby.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Stay hydrated to prevent dehydration from hydrochlorothiazide, especially if you sweat heavily or have diarrhea/vomiting.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EXFORGE HCT vs ALDORIL D30, answered by our medical review team.
EXFORGE HCT is a Antihypertensive that works by EXFORGE HCT is a combination of amlodipine (a dihydropyridine calcium channel blocker), valsartan (an angiotensin II receptor blocker), and hydrochlorothiazide (a thiazide diuretic). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation. Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Hydrochlorothiazide increases excretion of sodium and water by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EXFORGE HCT and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EXFORGE HCT is: One tablet orally once daily. Initial dose based on previous antihypertensive therapy; maximum dose is one tablet of 10 mg amlodipine/320 mg valsartan/25 mg hydrochlorothiazide per day.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EXFORGE HCT and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EXFORGE HCT is classified as Category C. First trimester: Drugs acting on renin-angiotensin system (ARB/ACEi component: valsartan) associated with increased risk of fetal renal dysfunction, oligohydramnios, skull ossifica. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.